Skip to content

IVF Versus Gonadotropin Therapy in Women With CC Resistant PCOS

In Vitro Fertilization Versus Gonadotropin Therapy in Women With Clomiphene Citrate Resistant Polycystic Ovarian Syndrome

Status
Withdrawn
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02458963
Enrollment
0
Registered
2015-06-01
Start date
2016-01-31
Completion date
2017-05-31
Last updated
2017-05-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility, Polycystic Ovarian Syndrome

Keywords

PCOS, Clomiphene citrate resistant, Gonadotropin, IVF

Brief summary

The purpose of this study is to compare the efficacy of in vitro fertilization (IVF) versus gonadotropin therapy in infertile women having clomiphene citrate (CC) resistant polycystic ovarian syndrome (PCOS).

Detailed description

Women will be randomly divided into two groups; IVF group and gonadotropin group. Women in the IVF group will undergo one full IVF cycle. Women in the gonadotropin group will be subjected to ovarian stimulation for 6 months with the gonadotropin low-dose step-down protocol.

Interventions

PROCEDUREIVF

Women will undergo one IVF cycle

Women will be subjected to ovarian stimulation for 6 months with the gonadotropin low-dose step-down protocol

Sponsors

Mohamed Sayed Abdelhafez
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 35 Years
Healthy volunteers
No

Inclusion criteria

* Infertile women with PCOS as defined by the Rotterdam criteria. * CC resistance (defined as failure of ovulation after receiving 150 mg/day of CC for 5 consecutive days per cycle, for at least 3 consecutive cycles).

Exclusion criteria

* Age \< 20 or \> 35 years. * Presence of any infertility factor other than anovulatory PCOS. * Previous history of ovarian surgery or surgical removal of one ovary. * Previous exposure to cytotoxic drugs or pelvic irradiation. * Oral hypoglycemic or hormonal therapy either currently or in the preceding 3 months. * Metabolic or hormonal abnormalities.

Design outcomes

Primary

MeasureTime frameDescription
Live birth rate9 monthsNumber of live births divided by the number of women

Secondary

MeasureTime frameDescription
Clinical pregnancy rate6-8 weeks gestational ageNumber of clinical pregnancies divided by the number of women
Multifetal pregnancy rate12 weeks gestational ageNumber of multifetal pregnancies divided by the number of clinical pregnancies
Miscarriage rate12 weeks gestational ageNumber of first trimester miscarriages (before 12 weeks gestational age) divided by the number of clinical pregnancies
Incidence of early ovarian hyperstimulation syndrome (OHSS)Within 9 days of final triggering of oocyte maturationIncidence of OHSS within 9 days of final triggering of oocyte maturation

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026